ClinicalTrials.gg
CompletedNCT02896127Updated Dec 30, 2020Results posted

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

A Phase 3 interventional study of Secukinumab and Placebo in Ankylosing Spondyloarthritis, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.

Enrollment
4th of 20
458 · median 223
Started
2016
with 3 others
Phase 3
11 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
15 of 20
Novartis Pharmaceuticals

Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 4th largest by enrollment, is one of 4 that started in 2016, is one of 11 in phase 3, and was the 11th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing secukinumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to demonstrate safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at week 16 and long term safety up to Week 52.

Read the detailed description

This multicenter study used a randomized, double-blind, placebo-controlled, parallel-group design. A screening period running up to 10 weeks before randomization was used to assess eligibility, followed by 52 weeks of treatment.

At baseline, subjects were randomized to one of the two treatment groups:

  • Group 1: 300 subjects, secukinumab 150 mg (1 mL, 150 mg/mL) s.c. pre-filled syringes (PFS) at BSL, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4
  • Group 2: 150 subjects, placebo (1 mL) s.c. PFS at BSL, Weeks 1, 2, 3, 4, 8, and 12, followed by secukinumab 150 mg (1 mL, 150 mg/mL) administration every four weeks starting at Week 16

The subjects were stratified at randomization according to the region (China and non-China). Approximately 70% of randomized subjects were from China (327 Chinese subjects) in order to evaluate the efficacy and safety in this subject population. No more than 30% TNFα inhibitor inadequate responders (TNF-IR) subjects were to be enrolled in the study.

Starting at Week 16, all subjects switched to open-label secukinumab 150 mg, including all placebo subjects; however, all subjects and investigators/site staff remained blinded to the original randomized treatment group assignment (150 mg vs placebo). Study treatment continued up to Week 48.

An end of treatment visit was done 4 weeks after last study treatment administration and a post treatment follow-up visit was done 12 weeks after last study treatment administration for all subjects (regardless of whether they completed the entire study as planned or discontinued prematurely).

Subjects were instructed in detail how to self-administer the s.c. injection using PFS. Each injection was administered into an appropriate injection site of the body (thighs, arms, or abdomen). All injections were performed at the study site. Site personnel administered the injections to subjects who were not able to, or felt insecure to self-administer. Rescue medication was not allowed until Week 20. However, subjects who were deemed by the investigator not to be benefiting from the study treatment based on safety and efficacy assessments or for any reason of their own accord were free to discontinue participation in the study at any time.

03

Conditions studied

  • Ankylosing Spondyloarthritis

Keywords

  • Ankylosing Spondyloarthritis
  • Axial spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or non-pregnant, non-lactating female patients at least 18 years of age

Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS:

  • Active AS assessed by BASDAI ≥4 (0-10) at Baseline
  • Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at Baseline
  • Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline Patients should have had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or Patients who are regularly taking NSAIDs (including COX-1 or COX-2 inhibitors) as part of their AS therapy are required to be on a stable dose for at least 2 weeks before randomisation Patients who have been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to randomization or have been intolerant to at least one administration of an anti-TNFα agent

Exclusion criteria

Exclusion Criteria:

  • Chest X-ray or MRI with evidence of ongoing infectious or malignant process

    • Patients taking high potency opioid analgesics
    • Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor
    • Pregnant or nursing (lactating) women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Secukinumab 150 mg s.c. Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16

    Drug: Secukinumab

  • Placebo comparator
    Placebo

    Placebo s.c.

    Drug: Placebo

Interventions

  • Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment.

    Also known as: AIN457

  • DrugPlacebo

    Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly

06

What researchers measure

Primary outcomes

  1. The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)

    ASAS20 response is defined as an improvement of ≥20% and ≥1 units on a scale of 10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain

    Time frame: Week 16

Secondary outcomes

  1. The Proportion of Participants Who Achieve an ASAS40 Response

    ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

    Time frame: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.

  2. Change in hsCRP Over Time

    hsCRP is measured as a marker of inflammation from blood samples during the study The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

    Time frame: Change from baseline to Week 16. The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.

  3. Percentage of Participants Who Achieve an ASAS 5/6 at Week 16

    The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

    Time frame: Week 16: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.

  4. Participants With BASDAI Response at 16 Weeks

    The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

    Time frame: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.

  5. Change in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 16

    The Physical Component Summary (PCS) SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

    Time frame: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.

  6. Change in ASQoL Score Over Time

    The Ankylosing Spondylitis Quality of Life (ASQoL) is an instrument to assess health-related quality of life among adult patients with Ankylosing Spondylitis. Each statement on the ASQoL is given a score of "1" or "0". A score of "1" is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL).

    Time frame: change from baseline to Week 16

  7. The Proportion of Patients Who Achieve an ASAS Partial Remission

    The The Assessment in SpondyloArthritis International Society (ASAS) partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10 The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

    Time frame: Week 16

07

Results

Posted Dec 30, 2020

Participant flow

The majority of subjects completed 52 weeks of treatment. After Week 16 all participants originally assigned to placebo switched to AIN457 150 mg s.c. Four out of the 153 assigned to the placebo group discontinued before Week 16.

COMPLETED WEEK 52
Participant flow — COMPLETED WEEK 52
MilestoneSecukinumabPlacebo
Started305153
Completed278142
Not completed2711
Withdrew: Adverse event92
Withdrew: Lack of efficacy23
Withdrew: Lost to follow-up01
Withdrew: Physician decision11
Withdrew: Pregnancy20
Withdrew: Withdrawal by subject124
Withdrew: Technical problems10
COMPLETED POST-TREATMENT FOLLOW UP
Participant flow — COMPLETED POST-TREATMENT FOLLOW UP
MilestoneSecukinumabPlacebo
Started280139
Completed276134
Not completed45
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up01
Withdrew: Physician decision10
Withdrew: Pregnancy10
Withdrew: Protocol violation01

Outcome measures

PrimaryThe Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)

ASAS20 response is defined as an improvement of ≥20% and ≥1 units on a scale of 10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)
ParticipantsSecukinumabPlacebo
The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)17856
Statistical analysis
  • Secukinumab vs Placebo · Regression, Logistic · p = <.0001 · Odds ratio (or): 2.47 · 95% CI 1.65 to 3.69
SecondaryThe Proportion of Participants Who Achieve an ASAS40 Response

ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

Time frame:
The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Reported as:
Count of participants · Participants
The Proportion of Participants Who Achieve an ASAS40 Response
ParticipantsSecukinumabPlacebo
The Proportion of Participants Who Achieve an ASAS40 Response13827
SecondaryChange in hsCRP Over Time

hsCRP is measured as a marker of inflammation from blood samples during the study The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

Time frame:
Change from baseline to Week 16. The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Reported as:
Mean · mg/l
Change in hsCRP Over Time
mg/lSecukinumabPlacebo
Change in hsCRP Over Time-11.78 ± 22.919-0.79 ± 20.023
SecondaryPercentage of Participants Who Achieve an ASAS 5/6 at Week 16

The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

Time frame:
Week 16: The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an ASAS 5/6 at Week 16
percentage of participantsSecukinumabPlacebo
Percentage of Participants Who Achieve an ASAS 5/6 at Week 1650.5 (44.7 to 56.3)19.2 (13.3 to 26.7)
SecondaryParticipants With BASDAI Response at 16 Weeks

The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

Time frame:
The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Reported as:
Number · percent of participants
Participants With BASDAI Response at 16 Weeks
percent of participantsSecukinumabPlacebo
Participants With BASDAI Response at 16 Weeks41.7 (36.0 to 47.6)22.6 (16.3 to 30.4)
SecondaryChange in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 16

The Physical Component Summary (PCS) SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

Time frame:
The secondary outcome analysis occurred only at Week 16. Thus, while data were collected beyond week 16, they were not part of the secondary outcomes.
Reported as:
Number · percent of participants
Change in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 16
percent of participantsSecukinumabPlacebo
Change in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 1671.8 (66.3 to 76.7)61.1 (52.7 to 68.8)
SecondaryChange in ASQoL Score Over Time

The Ankylosing Spondylitis Quality of Life (ASQoL) is an instrument to assess health-related quality of life among adult patients with Ankylosing Spondylitis. Each statement on the ASQoL is given a score of "1" or "0". A score of "1" is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL).

Time frame:
change from baseline to Week 16
Reported as:
Mean · scores
Change in ASQoL Score Over Time
scoresSecukinumabPlacebo
Change in ASQoL Score Over Time-4.6 ± 4.98-2.6 ± 4.28
SecondaryThe Proportion of Patients Who Achieve an ASAS Partial Remission

The The Assessment in SpondyloArthritis International Society (ASAS) partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10 The number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.

Time frame:
Week 16
Reported as:
Number · percent of participants
The Proportion of Patients Who Achieve an ASAS Partial Remission
percent of participantsSecukinumabPlacebo
The Proportion of Patients Who Achieve an ASAS Partial Remission17.7 (13.6 to 22.6)7.5 (4.0 to 13.4)

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment up to week 52. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any AIN457 150 mg0/453 (0%)33/453 (7.3%)282/453 (62.3%)
Placebo0/153 (0%)3/153 (2%)60/153 (39.2%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventAny AIN457 150 mgPlacebo
Anal abscessInfections and infestations3/4530/153
PyelonephritisInfections and infestations0/4531/153
Ankylosing spondylitisMusculoskeletal and connective tissue disorders1/4531/153
Acute psychosisPsychiatric disorders0/4531/153
Pneumonia mycoplasmalInfections and infestations2/4530/153
UreterolithiasisRenal and urinary disorders2/4530/153
Arteriosclerosis coronary arteryCardiac disorders1/4530/153
Ventricular extrasystolesCardiac disorders1/4530/153
Bronchogenic cystCongenital, familial and genetic disorders1/4530/153
Deafness neurosensoryEar and labyrinth disorders1/4530/153
Most frequent other events
Showing 10 of 22
Most frequent other events
EventAny AIN457 150 mgPlacebo
Upper respiratory tract infectionInfections and infestations145/45329/153
NasopharyngitisInfections and infestations46/45310/153
DiarrhoeaGastrointestinal disorders35/4536/153
HyperlipidaemiaMetabolism and nutrition disorders26/4531/153
Hepatic function abnormalHepatobiliary disorders24/4533/153
Alanine aminotransferase increasedInvestigations24/4533/153
Mouth ulcerationGastrointestinal disorders18/4532/153
Oropharyngeal painRespiratory, thoracic and mediastinal disorders18/4532/153
White blood cell count decreasedInvestigations17/4530/153
Urinary tract infectionInfections and infestations16/4535/153

Baseline characteristics

The Full Analysis Set (FAS) was comprised of all subjects from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, subjects were evaluated according to the treatment assigned to at randomization, but actual stratum, if stratified randomization was used.

Age, Categorical
Age, Categorical(Participants)SecukinumabPlaceboTotal
<=18 years000
Between 18 and 65 years303152455
>=65 years213
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabPlaceboTotal
Female532174
Male252132384
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SecukinumabPlaceboTotal
Asian239130369
White642387
Other202
08

Study locations

44 sites
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Hefei, Anhui 230022, China
  • Novartis Investigative Site
    Beijing, Beijing 100039, China
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Xiamen, Fujian 361001, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 51000, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Urumqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Bengbu, 233004, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shanghai, 200127, China
  • Novartis Investigative Site
    Shanghai, 200433, China
  • Novartis Investigative Site
    Shanghai, China
  • Novartis Investigative Site
    Shanxi Province, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Zhejiang, China
  • Novartis Investigative Site
    Zhenjiang, China
  • Novartis Investigative Site
    Bruntal, Czech Republic 792 01, Czechia
  • Novartis Investigative Site
    Ostrava, Czech Republic 772 00, Czechia
  • Novartis Investigative Site
    Praha 11, Czech Republic 148 00, Czechia
  • Novartis Investigative Site
    Praha 2, Czech Republic 128 50, Czechia
  • Novartis Investigative Site
    Uherske Hradiste, 686 01, Czechia
  • Novartis Investigative Site
    Seoul, Seocho Gu 06591, Korea, Republic of
  • Novartis Investigative Site
    Busan, 602739, Korea, Republic of
  • Novartis Investigative Site
    Gwangju, 61469, Korea, Republic of
  • Novartis Investigative Site
    Incheon, 405 760, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 04763, Korea, Republic of
  • Novartis Investigative Site
    Reading, Berkshire RG1 5AN, United Kingdom
  • Novartis Investigative Site
    Bradford, West Yorkshire BD9 6RJ, United Kingdom
  • Novartis Investigative Site
    Bath, BA1 1RL, United Kingdom
  • Novartis Investigative Site
    Doncaster, DN2 5LT, United Kingdom
  • Novartis Investigative Site
    Hull, HU16 5JQ, United Kingdom
  • Novartis Investigative Site
    London, NW1, United Kingdom
  • Novartis Investigative Site
    Norwich, NR1 3SR, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
  • Novartis Investigative Site
    Wigan, WN6 9EP, United Kingdom
09

References and documents

Publications

  • Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19. PubMed 35305260 ↗
  • van der Horst-Bruinsma I, Miceli-Richard C, Braun J, Marzo-Ortega H, Pavelka K, Kivitz AJ, Deodhar A, Bao W, Porter B, Pournara E. A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. Rheumatol Ther. 2021 Dec;8(4):1775-1787. doi: 10.1007/s40744-021-00380-2. Epub 2021 Oct 7. PubMed 34618347 ↗
  • Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Senolt L, Wang Y, Qiu HM, Porter B, Haemmerle S. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. Chin Med J (Engl). 2020 Nov 5;133(21):2521-2531. doi: 10.1097/CM9.0000000000001099. PubMed 32925287 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in May 2018, 18 months.

Results were first posted in Dec 2020, 2 years 7 months after primary completion.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 18 months is below that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2016
First posted
Sep 12, 2016
StartActual
Oct 18, 2016
Primary completionActual
May 14, 2018
CompletionActual
Mar 19, 2019
Results first posted
Dec 30, 2020
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02896127
Responsible party
Sponsor
First posted
Sep 12, 2016
Start date
Oct 18, 2016
Primary completion
May 14, 2018
Completion
Mar 19, 2019
Results posted
Dec 30, 2020
Last update
Dec 30, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion